• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    2/10/26 4:35:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AIM alert in real time by email
    S-1/A 1 forms-1a.htm S-1/A

     

    As filed with the Securities and Exchange Commission on February 10, 2026

     

    Registration No. 333-292085

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 3

    TO

    FORM S-1

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    AIM ImmunoTech Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   2836   52-0845822
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification Number)

     

    2117 SW Highway 484

    Ocala FL 34473

    (352) 448-7797

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Thomas K. Equels

    Chief Executive Officer

    AIM ImmunoTech Inc.

    2117 SW Highway 484

    Ocala FL 34473

    (352) 448-7797

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Richard Feiner, Esq.

    Silverman, Shin & Schneider PLLC

    88 Pine Street, 22nd Floor

    New York, NY 10005

    (646) 822-1170

    [email protected]

     

    Barry I. Grossman, Esq.

    Matthew Bernstein, Esq.

    Ellenoff Grossman & Schole LLP

    1345 Avenue of the Americas, 11th Floor

    New York, NY 10105

    (212) 370-1300

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

      Large accelerated filer ☐ Accelerated filer ☐
             
      Non-accelerated filer ☒ Smaller reporting company ☒
             
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Amendment to the Registration Statement on Form S-1 (File No. 333-292085) is being filed as an “exhibits-only” filing solely to amend Item 16(a) of Part II thereof. Accordingly, this Amendment consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature page to the Registration Statement, and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted. Capitalized terms used and not otherwise defined in this Amendment have the meanings given them in the complete Registration Statement, the most recent version of which was filed on January 29, 2026.

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 13. Other Expenses of Issuance and Distribution

     

    The following is a statement of estimated expenses in connection with the issuance and distribution of the securities being registered, excluding dealer-manager fees. All expenses incurred with respect to the registration of the common stock will be borne by us. All amounts are estimates except the SEC registration fee and the FINRA filing fee.

     

    Item 

    Amount

    to be Paid

     
    SEC registration fee  $4,971.60 
    FINRA filing fee  $5,900.00 
    Legal fees and expenses  $120,000.00 
    Accounting fees and expenses   100,000.00 
    Subscription Agent, Information Agent and Warrant Agent Fees and Expenses   38,500.00 
    Miscellaneous expenses   7,862.00 
    Total  $272,262.00 

     

    Item 14. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law (the “DGCL”) inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys’ fees) actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee has met the applicable standard of conduct.

     

    Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.

     

    Section 102(b)(7) of the DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption) or (iv) for any transaction from which the director derived an improper personal benefit.

     

    Article Ninth of our Amended and Restated Certificate of Incorporation provides that we shall indemnify to the extent permitted by Delaware law any person whom it may indemnify thereunder, including directors, officers, employees and agents. Such indemnification (other than an order by a court) shall be made by us only upon a determination that indemnification is proper in the circumstances because the individual met the applicable standard of conduct. Advances for such indemnification may be made pending such determination. In addition, the Registrant’s Amended and Restated Certificate of Incorporation eliminates, to the extent permitted by Delaware law, personal liability of directors to the Registrant and its stockholders for monetary damages for breach of fiduciary duty as directors.

     

    The foregoing discussion of our amended and restated certificate of incorporation and Delaware law is not intended to be exhaustive and is qualified in its entirety by such certificate of incorporation or law.

     

    Insofar as the foregoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    II-1

     

     

    Item 15. Recent Sales of Unregistered Securities.

     

       Cost Basis Per Share of 
      

    Common Stock

    Post Split

      

    Common Stock

    Indirect-Post Split

       Common Stock- Post Split 
    Nancy Bryan  $179.41    —    2,918 
    3/21/2024  $39.00    —    384 
    12/2/2024  $23.00    —    226 
    12/13/2024  $21.30    —    245 
    12/31/2024  $19.80    —    263 
    1/15/2015  $19.00    —    274 
    1/31/2025  $20.19    —    258 
    2/14/2025  $12.02    —    433 
    2/28/2025  $13.50    —    386 
    3/14/2025  $11.60    —    449 
    David Chemerow  $25.10    —    641 
    2/28/2025  $13.50    —    193 
    3/14/2025  $11.60    —    448 
    Thomas Equels  $2,525.20    —    35,872 
    4/25/2022  $102.00    —    490 
    7/18/2022  $76.00    —    328 
    1/3/2023  $31.00    —    1,612 
    7/17/2023  $59.00    —    169 
    8/24/2023  $66.70    —    149 
    8/25/2023  $66.90    —    82 
    9/29/2023  $44.10    —    226 
    11/27/2023  $44.30    —    338 
    3/15/2024  $33.00    —    757 
    5/6/2024  $40.50    —    617 
    8/12/2024  $26.50    —    3,773 
    9/11/2024  $32.00    —    3,125 
    9/13/2024  $30.80    —    200 
    9/16/2024  $30.30    —    50 
    11/20/2024  $114.83    —    1,451 
    11/21/2024  $21.17    —    200 
    12/19/2024  $20.60    —    227 
    3/4/2025  $23.50    —    1,273 
    3/5/2025  $13.46    —    500 
    4/4/2025  $6.30    —    410 
    4/21/2025  $2.54    —    19,685 
    6/12/2025  $870.00    —    103 
    6/13/2025  $769.70    —    107 
    Ted Kellner  $   37,205      
       $   17,510      
       $   19,695      
    William Mitchell  $142.95    —    4,505 
    12/2/2024  $23.00    —    227 
    12/13/2024  $21.30    —    245 
    12/31/2024  $19.80    —    263 
    1/15/2025  $19.00    —    274 
    1/31/2025  $20.19    —    258 
    2/14/2025  $12.02    —    433 
    2/28/2025  $13.50    —    38 
    3/14/2025  $14.14    —    2,419 
    Peter Rodino  $259.50    —    3,435 
    4/25/2022  $102.00    —    49 
    1/3/2023  $31.00    —    806 
    3/15/2024  $33.00    —    379 
    5/6/2024  $40.50    —    309 
    8/12/2024  $26.50    —    1,887 
    4/4/2025  $26.50    —    5 
    Grand Total  $3,132.16    37,205    47,371 

     

    The foregoing issuances were made pursuant to employment agreements, reductions in salaries and compensation for directors serving on committees.

     

    The offers, sales and issuances of securities described above was deemed to be exempt from registration under the Securities Act in reliance on either Section 4(a)(2) in that they did not involve a public offering, or Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701.

     

    II-2

     

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a) Exhibits

     

    The following exhibits are being filed with this Registration Statement:

     

    Exhibit No.

      Description   Filed with this Report   Incorporated by Reference herein from Form or Schedule  

     

    Filing Date

      SEC File/Reg. Number
                         
    1.1   Form of Dealer Manager Agreement                
                         
    3.1(i)   Certificate of Incorporation as Amended and Restated through June 10, 2025       Form 8-K (Exhibit 3.1(i))   10/29/2025   001-27072
                         
    3.1.7   Form of Certificate of Designation of Series G Preferred Stock                
                         
    3.3   Amended and Restated By-Laws of Registrant       Form 8-K (Exhibit 3.7(ii)   2/26/2025   001-27072
                         
    4.1   Specimen certificate representing our Common Stock       Form 10-Q (Exhibit 4.1)   11/14/2024   001-27072
                         
    4.2   Rights Agreement, dated May 12, 2023 between AIM ImmunoTech Inc. and American Stock Transfer & Trust Company, LLC.       Form 8-A12B (Exhibit 4.6)   5-15-2023   001-27072
                         
    4.3   Amended and Restated Rights Agreement, dated as of November 14, 2017, between the Company and American Stock Transfer & Trust Company LLC. The Amended and Restated Right Agreement includes the Form of Certificate of Designation, Preferences and Rights of the Series A Junior Participating Preferred Stock, the Form of Rights Certificate and the Summary of the Right to Purchase Preferred Stock       Form 8-A12B (Exhibit 1)   11/14/2017   001-27072
                         
    4.4   Amended and Restated Rights Agreement, dated as of November 9, 2022, between the Company and American Stock Transfer & Trust Company LLC.       Form 8-A12B (Exhibit 4.4)   11/14/2022   001-27072
                         
    4.5   Amended and Restated Rights Agreement, dated as of February 9, 2023, between the Company and American Stock Transfer & Trust Company LLC.       Form 8-A12B/A (Exhibit 4.5)   2/10/2023   001-27072
                         
    4.6   Form of Indenture       Form S-3 (Exhibit 4.4)   1/21/2022   333-262280
                         
    4.7   Form of Warrant issued to Purchaser of facility       Form 10-K (Exhibit 4.8)   3/30/2018   001-27072
                         
    4.8   2018 Rights Offering Form of Non-Transferrable Subscription Rights Certificate       Form S-1/A (Exhibit 4.14)   2/6/2019   333-229051
                         
    4.9   2018 Rights Offering Form of Warrant Agreement       Form 8-K (Exhibit 4.1)   2/27/2019   001-27072
                         
    4.10   2018 Rights Offering Form of Warrant Certificate       Form S-1/A (Exhibit 4.15)   2/6/2019   333-229051
                         
    4.11   2018 Rights Offering Warrant Agency Agreement with American Stock Transfer & Trust       Form 8-K (Exhibit 4.1)   3/8/2019   001-27072
                         
    4.12   Description of Common Stock.       Form 10-K (Exhibit 4.11)   3/27/2025   001-270072
                         
    4.13   Form of Warrant Agency Agreement between AIM and Equiniti Trust Company, LLC       Form 8-K (Exhibit 4.1)   3/8/2019   001-270072
                         
    4.14   Form of Warrant                
                         
    4.15   Form of Warrant Agency Agreement between AIM and Equiniti Trust Company, LLC                

     

    II-3

     

     

    Exhibit No.

      Description   Filed with this Report   Incorporated by Reference herein from Form or Schedule  

     

    Filing Date

      SEC File/Reg. Number
                         
    4.16   Form of Non-Transferrable Subscription Rights Certificate                
                         
    4.17+ †   2024 Class A/B Common Stock Purchase Warrant       Form 8-K (exhibit 4.1)   6/3/24   001-27072
                         
    4.18+ †   2024 Class C Common Stock Purchase Warrant with Armistice Capital Master Fund Ltd       Form 8-K (Exhibit 4.1)   10/1/2024   001-27072
                         
    4.19+ †   2024 Class D Common Stock Purchase Warrant with Armistice Capital Master Fund Ltd       Form 8-K (Exhibit 4.2)   10/1/2024   001-27072
                         
    4.20+ †   2025 Class E/F Warrants       Form S-1A no. 3 (exhibit 4.26)   7/15/2025   33-3284443
                         
    4.21+ †   2025 Pre-Funded Warrant       Form S-1A no. 3 (exhibit 4.27)   7/15/2025   33-3284443
                         
    5.1   Opinion of Silverman Shin & Schneider PLLP       Form S-1A no. 1 (exhibit 5.1)   1/23/2026   33-292085
                         
    10.1   Form of Confidentiality, Invention and Non-Compete Agreement       Form S-1 (Exhibits)   11/2/1995   33-93314
                         
    10.2   Supply Agreement with HollisterStier Laboratories LLC dated December 5, 2005       Form 10-K (Exhibit 10.46)   4/3/2006   001-13441
                         
    10.3  

    Amendment to Supply Agreement with HollisterStier Laboratories LLC dated February 25, 2010

          Form 10-K (Exhibit 10.68)   3/12/2010   001-13441
                         
    10.4   Amendment to Supply Agreement with HollisterStier Laboratories LLC executed September 9, 2011       Form 10-K (Exhibit 10.22)   3/14/2012   001-13441
                         
    10.5   Early Access Agreement with Impatients N.V. dated August 3, 2015+†       Form 10-Q (Exhibit 10.1)   11/16/2015   000-27072
                         
    10.6+ †   Addendum to Early Access Agreement with Impatients N.V. dated October 16, 2015       Form 10-Q (Exhibit 10.2)   11/16/2015   000-27072
                         
    10.7+ †   Licensing Agreement dated April 13, 2016 with Lonza Sales AG       Form 10-Q/A (Exhibit 10.2)   8/29/2016   000-27072
                         
    10.8+ †   Amended and Restated Early Access Agreement with Impatients N.V. dated May 20, 2016.       Form 8-K/A (Exhibit 10.1)   5/8/2017   000-27072
                         
    10.9   December 13, 2016 Amendment No. 1 to Amended and Restated Early Access Agreement with Impatients N.V.       Form 10-K (Exhibit 10.45)   3/30/2018   001-27072
                         
    10.10   June 28, 2017 Amendment No. 2 to Amended and Restated Early Access Agreement with Impatients N.V.       Form 10-K (Exhibit 10.46)   3/30/2018   001-27072
                         
    10.11   February 14, 2018 Amendment No. 3 to Amended and Restated Early Access Agreement with Impatients N.V.       Form 10-K (Exhibit 10.47)   3/30/2018   001-27072
                         
    10.12   March 26, 2018 Amendment No. 4 to Amended and Restated Early Access Agreement with Impatients N.V.       Form 10-K (Exhibit 10.48)   3/30/2018   001-27072

     

    II-4

     

     

    Exhibit No.

      Description   Filed with this Report   Incorporated by Reference herein from Form or Schedule  

     

    Filing Date

      SEC File/Reg. Number
                         
    10.13   2018 Equity Incentive Plan *       Form DEF-14A (Appendix A)   8/3/2018   001-27072
                         
    10.14   October 9, 2018, Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center       Form 10-Q (Exhibit 10.1)   11/14/2018   001-27072
                         
    10.15   March 20, 2020 Amendment to 2017 Material Transfer and Research Agreement with Roswell Park Cancer Institute       Form 8-K (Exhibit 10.1)   3/26/2020   001-27072
                         
    10.16+ †   July 1, 2020, Material Transfer and Research Agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd.       Form 10-Q (Exhibit 10.3)   8/14/2020   001-27072
                         
    10.17+ †   July 6, 2020, Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center.       Form 10-Q (Exhibit 10.4)   8/14/2020   001-27072
                         
    10.18+ †   August 6, 2020, Project Work Order with Amarex Clinical Research LLC.       Form 10-Q (Exhibit 10.5)   8/14/2020   001-27072
                         
    10.19   November 10, 2020 employment agreement with Thomas K. Equels. *       Form 10-Q (Exhibit 10.1)   11/12/2020   001-27072
                         
    10.20   December 22, 2020 Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen       Form 10-K (Exhibit 10.75)   3/31/2021   001-27072
                         
    10.21+ †   December 30, 2020 Amendment to Project Work Order with Amarex Clinical Research LLC.       Form 10-K (Exhibit 10.78)   3/31/2021   001-27072
                         
    10.22   December 23, 2020 Amendment to Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen       Form 10-K (Exhibit 10.79)   3/31/2021   001-27072
                         
    10.23   March 24, 2021 employment agreement with Peter Rodino*       Form 10-K (Exhibit 10.80)   3/31/2021   001-27072
                         
    10.24+ †   Material Transfer and Research agreement with Roswell Park Comprehensive Cancer Center executed on April 14, 2021       Form 10-Q (Exhibit 10.2)   5/17/21   001-27072
                         
    10.25+ †   May 12, 2021 Amendment to the Renewed Sales, Marketing, Distribution and Supply Agreement with GP Pharm.       Form 10-Q (Exhibit 10.5)   5/17/21   001-27072
                         
    10.26+ †  

    March 1, 2022 Consulting Agreement with Foresite Advisors, LLC pursuant to which Robert Dickey IV will serve as the Company’s Chief Financial Officer*

          Form 10-K (Exhibit 10.78)   3/31/2022   001-27072
                         
    10.27   March 8, 2022 Change order to Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen.       Form 10-K (Exhibit 10.82)   3/31/2022   001-27072
                         
    10.28+ †   April 7, 2022 Project Work Order with Amarex Clinical Research LLC.to manage Phase 2 clinical trial in advanced pancreatic cancer patients       Form 8-K (Exhibit 10.1)   4/12/2022   001-27072
                         
    10.29+ †   June 13, 2022 Project Work Order with Amarex Clinical Research LLC. for a Randomized Double Blind, Placebo Controlled study to Evaluate the Efficacy and Safety of Ampligen in Patients with Post Covid Conditions       Form 8-K (Exhibit 10.1)   6/17/2022   001-27072
                         
    10.30   June 16, 2022 Lease agreement entered into with New Jersey Economic Development Authority for 5,210 square-foot R&D facility at the New Jersey Bioscience Center       Form 8-K (Exhibit 10.1)   6/21/2022   001-27072
                         
    10.31   October 5, 2022 Lease extension for Riverton office       Form 10-Q (Exhibit 10.4)   11/14/2022   001-27072
                         
    10.32+ †   October 11, 2022 Material Transfer and Research Agreement with University of Pittsburgh       Form 10-Q (Exhibit 10.5)   11/14/2022   001-27072
                         
    10.33+ †   October 21, 2022 Material Transfer and Research Agreement with University of Pittsburgh       Form 10-Q (Exhibit 10.6)   11/14/2022   001-27072
                         
    10.34   December 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc.       Form 10-K (Exhibit 10.93)   3/31/23   001-27072

     

    II-5

     

     

    Exhibit No.

      Description   Filed with this Report   Incorporated by Reference herein from Form or Schedule  

     

    Filing Date

      SEC File/Reg. Number
                         
    10.35+ †   January 13, 2023 Study Support Agreement with Erasmus University Medical Center Rotterdam       Form 10-K (Exhibit 10.94)   3/31/2023   001-27072
                         
    10.36+ †   January 13, 2023 Co-ordination Agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV       Form 10-K (Exhibit 10.95)   3/31/2023   001-27072
                         
    10.37   March 1, 2023 Extension Agreement with Foresite Advisors LLC*       Form 10-K (Exhibit 10.96)   3/31/2023   001-27072
                         
    10.38   April 4, 2023 Unrestricted Grant Agreement with Erasmus University Medical Center       Form 8-K (Exhibit 10.1)   4/7/2023   001-27072
                         
    10.39   April 5, 2023 Independent Contractor Service Agreement with Casper H.J van Eijck       Form 8-K (Exhibit 10.2)   4/7/2023   001-27072
                         
    10.40   April 19, 2023 Equity Distribution Agreement with Maxim Group, LLC       Form 8-K (Exhibit 10.1)   4/19/2023   001-27072
                         
    10.41+ †   Material Transfer and Research Agreement, dated as of May 22, 2023, with Japanese National Institute of Infectious Disease †       Form 8-K (Exhibit 10.1)   5/30/2023   001-27072
                         
    10.42   September 20, 2023 Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center       Form 8-K (Exhibit 10.1)   9/29/2023   001-27072
                         
    10.43   February 16, 2024 Note Purchase Agreement with Streeterville Capital LLC       Form 8-K (Exhibit 10.1)   2/20/2024   001-27072
                         
    10.44   February 16, 2024 Promissory Note with Streeterville Capital LLC       Form 8-K (Exhibit 10.2)   2/20/2024   001-27072
                         
    10.45   Atlas Equity Purchase Agreement       Form 10-K (Exhibit 10.104)   4/1/2024   001-27072
                         
    10.46   Atlas Registration Rights Agreement       Form 10-K (Exhibit 10.105)   4/1/2024   001-27072
                         
    10.47   October 4, 2023 Lease extension for Riverton office       Form S-1 (Exhibit 10.106)   4/19/2024   001-27072
                         
    10.48   March 15, 2024 Addendum 1 to Lease for Ocala office       Form S-1 (Exhibit 10.107)   4/16/2024   001-27072
                         
    10.49   Form of Securities Purchase Agreement, dated as of May 31, 2024, by and among the Company and a Purchaser       Form 8-K (Exhibit 10.1)   6/3/2024   001-27072
                         
    10.50   August 12, 2024 Amendment to Employment Agreement for Thomas K Equels*       Form 10-Q (Exhibit 10.4)   8/14/2024   001-27072
                         
    10.51   August 12, 2024 Amendment to Employment Agreement for Peter W Rodino III*       Form 10-Q (Exhibit 10.5)   8/14/2024   001-27072

     

    II-6

     

     

    Exhibit No.

      Description   Filed with this Report   Incorporated by Reference herein from Form or Schedule  

     

    Filing Date

      SEC File/Reg. Number
                         
    10.52   September 11, 2024 Amendment to Employment Agreement for Thomas K Equels*       Form 8-K (Exhibit 10.1)   9/12/2024   001-27072
                         
    10.53   September 11, 2024 Amendment to Employment Agreement for Peter W. Rodino III*       Form 8-K (Exhibit 10.2)   9/12/2024   001-27072
                         
    10.54   September 30, 2024 Securities Purchase Agreement       Form 8-K (Exhibit 10.1)   10/1/2024   001-27072
                         
    10.55   September 30, 2024 Placement Agency Agreement with Maxim Group LLC       Form 8-K (Exhibit 1.1)   10/1/2024   001-27072
                         
    10.56   September 19, 2024 Lease extension for Riverton office       Form 10-Q (Exhibit 10.15)   11/14/2024   001-27072
                         
    10.57   Class A/B Common Stock Purchase Warrant with Armistice       Form 8-K (Exhibit 4.1)   6/3/2024   001-27072
                         
    10.58   Class C Common Stock purchase warrant with Armistice       Form 8-K (Exhibit 4.1)   10/1/2024   001-27072
                         
    10.59   Class D Common Stock Purchase Warrant with Armistice       Form 8-K (Exhibit 4.2)   10/1/2024   001-27072
                         
    10.60   Form of Lock-up Agreement       Form S-1/A (Exhibit 10.119)   2/3/2025   333-284443
                         
    21.1   List of Subsidiaries       Form 10-K (Exhibit 2.1)   3/27/2025   001-27072
                         
    23.1   Consent of BDO USA, P.C.                
                         
    97.1   Company Clawback Policy       Form 10-K (Exhibit 97.1)   4/1/2024   001-27072
                         
    99.1   Form of Instructions as to Use of Subscription Rights Certificates                
                         
    99.2   Form of Letter to Shareholders who are Record Holders                
                         
    99.3   Form of Letter to Brokers, Dealers, Banks and Other Nominees                
                         
    99.4   Form of Broker Letter to Clients Who are Beneficial Holders                
                         
    99.5   Form of Beneficial Owner Election Form                
                         
    99.6   Form of Nominee Holder Certification                
                         
    99.7   Form of Notice of Important Tax Information                
                         
    107   Filing Fee Table       Form S-1 (Exhibit 107)   December 12, 2025   333-292085

     

    * Indicates management contract or compensatory plan or arrangement.

     

    + Schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

     

    † A portion of this Exhibit has been omitted as it contains information that (i) is not material and (ii) would be competitively harmful if publicly disclosed.

     

    II-7

     

     

    (b) Financial Statement Schedules

     

    All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.

     

    Item 17. Undertakings

     

    (a) The undersigned registrant hereby undertakes:
       
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i) To include any prospectus required by section 10(a)(3) of the Securities Act;
         
      (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

      Provided, however, that paragraphs (a)(1)(i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
       
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
       
    (4) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

      (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

    II-8

     

     

      (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
         
      (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
         
      (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
       
    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
       
    (d) The undersigned registrant hereby undertakes that:
       
    (1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and
       
    (2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-9

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ocala, Florida on February 10, 2026.

     

      AIM IMMUNOTECH INC.
         
      By:  /s/ Thomas K. Equels
        Thomas K. Equels
        Chief Executive Officer and President

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

     

    SIGNATURE   TITLE   DATE
             
    /s/ Thomas K. Equels       February 10, 2026
    Thomas K. Equels   Chief Executive Officer and Director    
             
    /s/ Robert Dickey IV       February 10, 2026
    Robert Dickey IV   Chief Financial Officer    
             
    /s/ Thomas K. Equels*       February 10, 2026
    William Mitchell   Director    
             
    /s/ Thomas K. Equels*       February 10, 2026
    Nancy Bryan   Director    
             
    /s/ Thomas K. Equels*       February 10, 2026
    David Chemerow   Director    
             

    /s/ Thomas K. Equels*

          February 10, 2026
    Ted Kellner   Director    

     

     

    * As attorney in fact.

     

    II-10

     

    Get the next $AIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM's strategic emphasis on pancreatic cancer. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:40 PM ESTPresenter: Thomas K. Equels, MS JD, Chief Executive Officer Registration Link: Here S

    2/6/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

    OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" study) (see: ClinicalTrials.gov NCT05927142). This is a follow-up Phase 2 to a 57-subject early access program ("EAP") of Ampligen as a monotherapy in late-stage pancreatic cancer, where Ampligen was associated with median survival of 19.7 mo

    2/5/26 8:40:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

    OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today changes to the previously announced key dates relating to its proposed rights offering (the "Rights Offering"). Except as expressly amended herein, the terms of the Rights Offering remain unchanged. Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $12 million, less expenses related to the Rights Offering. The Subscription Rights will be non-transfera

    1/27/26 4:35:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/10/26 4:35:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/5/26 8:40:53 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

    1/29/26 4:31:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:16 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:19 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:17 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Kellner Ted D

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    7/21/25 4:10:22 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:16 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group resumed coverage on AIM ImmunoTech with a new price target

    Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00

    2/9/21 4:10:39 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by AIM ImmunoTech Inc.

    SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)

    11/14/24 3:21:36 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    9/11/24 5:40:58 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Leadership Updates

    Live Leadership Updates

    View All

    AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

    OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an

    2/26/25 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

    Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo

    12/12/24 3:00:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kellner Group Announces Support from Another Former AIM Senior Executive

    Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t

    12/12/24 8:16:14 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Financials

    Live finance-specific insights

    View All

    AIM ImmunoTech Announces Stock Dividend

    OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will

    12/30/25 5:10:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business

    3/27/25 8:05:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    – Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu

    11/15/24 7:29:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care